AletheiaHQ
Sign In
DIR-E8-IQ0-Q7KB/LVL 5·Leveraged OperationsHigh-leverage, capital-intensive cell operations. Requires fronted capital or established legal infrastructure. Examples: fronting $10k to lease warehouse space ahead of a known logistics fracture; forming a joint entity to secure and sub-license a dormant government patent for recurring royalties./85% confidence
Return to Directory

Capture SBIR Vendor Procurement via FOIA-Enabled Cartel

Organization
NSF SBIR Phase I program creating research capital without commercial procurement infrastructure
Sector
Specialized gene therapy CROs seeking qualified SBIR-funded clients
Location
Location unspecified

Source Reference

https://www.nsf.gov/awardsearch/showAward?AWD_ID=2604905

// Procurement// Biotech// Negotiation// Grant Writing// Compliance// Data Scraping// Open-Source Intelligence// Health Policy & Regulation

Executive Context

AICONIC BIOSCIENCES received $305K NSF SBIR Phase I funding for gene therapy research but faces a severe commercial execution gap between their research deliverables and the $100M+ required for FDA approval and market access. The SBIR program creates research capital without commercial infrastructure, generating multiple asymmetric opportunities around vendor procurement, commercial intelligence, and process IP capture.

Catalyst / Timing

AICONIC has $305K SBIR money that MUST be spent within 18 months on specific technical deliverables, but lacks established vendor relationships and procurement expertise for specialized gene therapy CRO services.

Projected Yield

$30K-$50K margin on AICONIC's vendor spend; scaled to $200K-$400K annually across 10+ SBIR biotechs

Structural Friction

• Vulnerability: AICONIC has $305K SBIR money that MUST be spent within 18 months on specific technical deliverables, but lacks established vendor relationships and procurement expertise for specialized gene therapy CRO services. • Capital yield: $30K-$50K margin on AICONIC's vendor spend; scaled to $200K-$400K annually across 10+ SBIR biotechs • Resource capture: Exclusive vendor referral agreements with specialized gene therapy CROs • Sovereignty yield: Control over procurement gateway for SBIR-funded gene therapy research • Required vectors: Vector: FOIA/Public Records, Vector: Biotech Vendor Landscape, Vector: Legal Contracting, Vector: Business Development

Required Capabilities

  • Vector: FOIA/Public Records

    Primary executor: Phase 1: FOIA Intelligence Extraction: Submit FOIA request to NSF for AICONIC's SBIR Phase I proposal (excluding proprie

  • Vector: Biotech Vendor Landscape

    Supporting vector for: Capture SBIR Vendor Procurement via FOIA-Enabled Cartel

  • Vector: Legal Contracting

    Supporting vector for: Capture SBIR Vendor Procurement via FOIA-Enabled Cartel

  • Vector: Business Development

    Supporting vector for: Capture SBIR Vendor Procurement via FOIA-Enabled Cartel

Execution Protocol

Execution Protocol Locked

A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.